12,372 trials
Lymphoma
Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167
Hypercholesterolemia
Primary: Number of Participants With Adverse Events — 526; 415; 206; 38 Participants
Atherosclerotic Cardiovascular Disease
Primary: Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study — 11.1; 9.5…
Psoriasis
Primary: Percentage of Secukinumab 300 mg Participants Achieving PASI 75 at 16 Weeks — 65.3 Percentage of participants — p=<0.0001
Psoriasis
Primary: Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set) — 10; 2; 9; 1 Participants
Anesthesia, General
Primary: Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9 — 2.32 Minutes
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) — -1.61; -1.36 percent of HbA1c — p=0.005
Restless Legs Syndrome · Restless Legs Syndrome (RLS)
Primary: Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR Over Period — 9; 14; 10; 11 Participants
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% — 20.0; 12.2 Months — p=0.0003
Hypercholesterolemia · Heterozygous Familial
Primary: Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1 — -27.17; -6.77; -22.96; -10.62 Percent
Lung Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) According to Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) at 12 Months — 64.5; 54.6 mL/min — p=<0.0001
Chronic Idiopathic Constipation
Primary: Number of Durable Overall CSBM Responders, Mean Replacement Approach — 57; 88; 88 Participants
Scabies
Primary: Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies — 83; 86 Participants
Multiple Sclerosis
Primary: Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months) — 73…
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) — 28.3; 58.6 percentage of participants — p=0.001